Humoral Immunity — Med2Date

📋 Key Information Summary

📋

Humoral immunity is the antibody-mediated arm of adaptive immunity, providing defence against extracellular pathogens, toxins, and free viral particles via B cell–derived immunoglobulins.
Naïve B cells are activated through T-dependent pathways (requiring CD4⁺ T follicular helper cells) or T-independent pathways (via direct polyclonal activation by TI-2 antigens such as polysaccharides).
Following activation, B cells undergo clonal expansion, somatic hypermutation, and affinity maturation in germinal centres of secondary lymphoid organs.
Antibodies consist of two heavy and two light chains forming Y-shaped glycoproteins with a variable antigen-binding fragment (Fab) and a constant crystallisable fragment (Fc) that mediates effector functions.
Five immunoglobulin classes exist — IgG, IgA, IgM, IgD, and IgE — each with distinct tissue distribution, complement-activating capacity, and roles in immune defence.
IgG is the most abundant serum immunoglobulin; it crosses the placenta (providing neonatal passive immunity), mediates opsonisation, and activates the classical complement pathway.
IgA predominates at mucosal surfaces as secretory dimeric IgA (sIgA), neutralising pathogens at the portal of entry; deficiency is the most common primary immunodeficiency worldwide.
IgM is the first antibody produced during a primary immune response; pentameric IgM is a potent activator of the classical complement cascade.
The complement system comprises over 30 proteins activated via classical (antibody-dependent), lectin (mannose-binding lectin), or alternative (spontaneous C3 hydrolysis) pathways.
Complement activation generates anaphylatoxins (C3a, C5a) for chemotaxis, opsonins (C3b) for phagocytosis, and the membrane attack complex (C5b–9) for direct pathogen lysis.
Humoral immune deficiencies — including X-linked agammaglobulinaemia, common variable immunodeficiency (CVID), selective IgA deficiency, and complement deficiencies — present with recurrent sinopulmonary, encapsulated bacterial, and enteric infections.
Australian clinical practice monitors humoral immunity via serum immunoglobulin quantification (MBS item 69440), specific antibody titres post-vaccination, complement levels (CH50, C3, C4), and flow cytometric B cell subset analysis.

Introduction & Australian Epidemiology

Humoral immunity is the B cell and antibody-mediated arm of adaptive immunity, providing protection against extracellular pathogens, toxins, and free viral particles. Unlike cell-mediated immunity, which relies on cytotoxic T lymphocytes to eliminate intracellularly infected cells, humoral immunity functions primarily in the extracellular space — neutralising toxins, opsonising bacteria for phagocytosis, activating the complement cascade, and facilitating antibody-dependent cellular cytotoxicity (ADCC).

The central effector molecules of humoral immunity are immunoglobulins (antibodies), which are secreted by terminally differentiated B cells known as plasma cells. The generation of a robust humoral response requires the coordinated interaction of B cells, CD4⁺ T follicular helper (Tfh) cells, dendritic cells, and follicular dendritic cells within the germinal centres of secondary lymphoid organs — principally lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT).

Epidemiology of Humoral Immune Deficiency in Australia

Primary immunodeficiencies affecting humoral immunity are not rare in Australia. Selective IgA deficiency (sIgAD) affects approximately 1 in 300–700 individuals in Caucasian populations and is frequently underdiagnosed because many patients are asymptomatic. The Australasian Society of Clinical Immunology and Allergy (ASCIA) estimates that between 25,000 and 50,000 Australians live with clinically significant primary immunodeficiency, with antibody deficiencies constituting the largest category (~50 %).

Common variable immunodeficiency (CVID) has a prevalence of approximately 1 in 25,000. In Australia, the mean diagnostic delay for CVID is 5–7 years, during which patients may develop bronchiectasis, granulomatous disease, or autoimmune complications. X-linked agammaglobulinaemia (Bruton disease) is rarer (~1 in 100,000 male births) but presents in infancy with severe recurrent infections if intravenous or subcutaneous immunoglobulin replacement is not commenced promptly.

Acquired causes of impaired humoral immunity are also common. Chronic lymphocytic leukaemia (CLL), the most prevalent adult leukaemia in Australia (~1,400 new diagnoses annually per AIHW data), frequently causes hypogammaglobulinaemia through disruption of normal B cell development. Rituximab, an anti-CD20 monoclonal antibody widely prescribed for rheumatoid arthritis, ANCA-associated vasculitis, and haematological malignancies, depletes circulating B cells and can reduce immunoglobulin levels significantly with prolonged use.

Complement deficiencies are rarer but clinically significant. C2 deficiency is the most common classical pathway defect in European-descent populations (~1 in 20,000) and predisposes to encapsulated bacterial infections and systemic lupus erythematosus (SLE). Hereditary angioedema (C1-inhibitor deficiency) affects approximately 1 in 50,000 Australians and requires specific therapies including C1-esterase inhibitor concentrate (Berinert®), icatibant (Firazyr®), and lanadelumab (Takhzyro®).

⚠️

Clinical pearl: Any patient presenting with recurrent sinopulmonary infections (≥ 2 episodes of pneumonia per year, or ≥ 4 ear infections per year), particularly with encapsulated organisms such as Streptococcus pneumoniae or Haemophilus influenzae, should be evaluated for a humoral immune deficiency. Serum immunoglobulins (IgG, IgA, IgM) and a pre-vaccination specific antibody titre panel are appropriate first-line investigations.

B Cell Activation

B cell activation is the initiating event in the humoral immune response. Naïve B cells reside primarily in secondary lymphoid organs and circulate through blood and lymph. Upon encountering their cognate antigen, B cells become activated, proliferate, and differentiate into antibody-secreting plasma cells or long-lived memory B cells.

T-Dependent B Cell Activation

Most protein antigens require cognate T cell help for full B cell activation — the T-dependent (TD) pathway. This is the dominant mechanism for generating high-affinity antibodies and immunological memory.

1

Antigen Recognition

The B cell receptor (BCR), a membrane-bound immunoglobulin, binds native (unprocessed) antigen. Antigen is internalised, processed through the endosomal pathway, and presented on MHC class II molecules to CD4⁺ T cells.

2

Cognate T Cell Help

Antigen-primed CD4⁺ T follicular helper (Tfh) cells, located at the T–B border of the lymphoid follicle, recognise the peptide–MHC II complex on the B cell. Bidirectional co-stimulatory signals are exchanged: CD40L (T cell) ↔ CD40 (B cell), and ICOS (T cell) ↔ ICOS-L (B cell).

3

Cytokine-Mediated Differentiation

Tfh cells secrete IL-21 and IL-4, which drive B cell proliferation, class-switch recombination (CSR), and plasma cell differentiation. IL-21 is the principal cytokine for germinal centre formation and affinity maturation.

4

Germinal Centre Reaction

Activated B cells enter germinal centres, where they undergo somatic hypermutation (SHM) of immunoglobulin variable region genes. B cells with higher-affinity BCRs are preferentially selected by follicular dendritic cells presenting antigen in immune complexes — a process termed affinity maturation.

5

Differentiation into Effector & Memory Cells

Germinal centre B cells differentiate into high-affinity antibody-secreting plasma cells (some becoming long-lived bone marrow plasma cells) or memory B cells that provide rapid recall responses upon re-exposure.

T-Independent B Cell Activation

Certain antigens — particularly repetitive polysaccharide structures found on encapsulated bacterial capsules — can activate B cells without T cell help. This T-independent (TI) pathway is subdivided:

Type 1 TI (TI-1): Polyclonal activators such as bacterial lipopolysaccharide (LPS) that activate B cells via Toll-like receptors (TLR4). At high concentrations, TI-1 antigens activate B cells irrespective of BCR specificity.
Type 2 TI (TI-2): Highly repetitive epitopes (e.g., pneumococcal polysaccharide capsule) that extensively cross-link BCRs, delivering sufficient intracellular signal without T cell co-stimulation. TI-2 responses predominantly generate IgM (class switching is limited) and produce little immunological memory — this is why conjugate vaccines (e.g., 13vPCV) are superior to plain polysaccharide vaccines (23vPPV) in young children, as they convert the response from TI-2 to TD.

ℹ️

Australian vaccination implication: Children under 2 years of age have an immature TI-2 response. The Australian National Immunisation Programme therefore schedules 13-valent pneumococcal conjugate vaccine (13vPCV — Prevenar 13®) at 2, 4, and 12 months. The 23-valent polysaccharide vaccine (23vPPV — Pneumovax 23®) is not recommended before age 2 years and is used as a booster in high-risk groups from age 4 years.

Clinical Relevance of B Cell Activation Defects

Defects at any stage of B cell activation lead to impaired humoral immunity. X-linked agammaglobulinaemia (XLA) results from mutations in BTK (Bruton tyrosine kinase), which is essential for pre-B cell receptor signalling; affected males have virtually absent mature B cells and immunoglobulins. Hyper-IgM syndromes caused by CD40L or CD40 mutations prevent the CD40–CD40L interaction required for germinal centre formation, resulting in markedly elevated IgM with deficient IgG, IgA, and IgE.

Antibody Structure & Function

Antibodies (immunoglobulins) are Y-shaped glycoprotein molecules secreted by plasma cells. Understanding their structure is essential to comprehending their diverse effector functions and the clinical consequences of structural abnormalities.

Basic Structure

Each antibody monomer comprises:

Two identical heavy (H) chains (~50 kDa each): The heavy chain constant region determines the immunoglobulin class (isotype) — γ (IgG), α (IgA), μ (IgM), δ (IgD), or ε (IgE). Heavy chains contain 3–4 constant domains (CH1–CH4) and one variable domain (VH).
Two identical light (L) chains (~25 kDa each): Either κ (kappa) or λ (lambda). In humans, the κ:λ ratio is approximately 2:1. Each light chain has one constant (CL) and one variable (VL) domain.
Disulphide bonds link heavy chains to each other and to light chains. A flexible hinge region between CH1 and CH2 allows the two antigen-binding arms to move independently.

Functional Regions

Region	Composition	Function
Fab (Fragment antigen-binding)	VH + CH1 + VL + CL	Antigen recognition and binding. Determines specificity through complementarity-determining regions (CDRs).
Fc (Fragment crystallisable)	CH2 + CH3 (+ CH4 in IgM/IgE)	Effector functions: binds Fc receptors (FcγR, FcεR, FcαR) on immune cells; binds C1q to activate complement; mediates placental transfer (IgG via FcRn); determines serum half-life.
Hinge region	Between CH1 and CH2	Flexibility enabling simultaneous binding of two epitopes at varying distances. Susceptible to proteolytic cleavage (papain cleaves above hinge → 2 Fab + Fc; pepsin cleaves below hinge → F(ab′)₂ + pFc′).

Antibody Effector Functions

Neutralisation

Toxin & Viral Neutralisation

Antibodies bind to pathogen surface molecules or toxins, physically blocking attachment to host cell receptors. Critical for defence against viruses (preventing cell entry) and bacterial toxins (e.g., tetanus toxoid antibodies).

Examples: Anti-tetanus IgG, anti-SARS-CoV-2 spike antibodies

Opsonisation

Fc Receptor-Mediated Phagocytosis

Antibody-coated pathogens are recognised by Fcγ receptors (FcγRI/CD64, FcγRII/CD32, FcγRIII/CD16) on macrophages and neutrophils, triggering phagocytosis, intracellular killing, and antigen presentation.

Example: IgG-mediated clearance of S. pneumoniae

Complement Activation

Classical Pathway Initiation

IgM (pentamer) and IgG (hexamer aggregation) bind C1q, initiating the classical complement cascade. Generates C3b for opsonisation (immune adherence), C3a/C5a for inflammation, and C5b–9 membrane attack complex (MAC) for direct lysis.

Example: IgM-mediated complement lysis of Gram-negative bacteria

ADCC

Antibody-Dependent Cellular Cytotoxicity

IgG-coated target cells are recognised by FcγRIII (CD16) on NK cells, triggering release of perforin and granzymes. Important for killing antibody-coated virus-infected cells and tumour cells.

Example: Rituximab (anti-CD20) mediates ADCC against B cell lymphomas

Mucosal Immunity

Secretory IgA Transcytosis

Dimeric IgA is transported across epithelial cells via the polymeric immunoglobulin receptor (pIgR), acquiring a secretory component that protects against proteolysis. sIgA neutralises pathogens and toxins at mucosal surfaces (gut, respiratory tract, urogenital tract).

Example: Rotavirus neutralisation in the gut lumen

Monoclonal Antibodies — Therapeutic Applications in Australia

Knowledge of antibody structure underpins the design of therapeutic monoclonal antibodies (mAbs), many of which are PBS-listed in Australia:

💊

Rituximab

MabThera® · Anti-CD20 chimeric mAb

Indications CLL, DLBCL, follicular lymphoma, rheumatoid arthritis, ANCA vasculitis

Mechanism Depletes CD20⁺ B cells via CDC, ADCC, and apoptosis

PBS status ✔ PBS Authority Required

💊

Omalizumab

Xolair® · Anti-IgE humanised mAb

Indications Severe allergic asthma, chronic spontaneous urticaria

Mechanism Binds free IgE at Cε3 domain, preventing FcεRI binding; reduces mast cell degranulation

PBS status ✔ PBS Authority Required

💊

Infliximab

Remicade® · Anti-TNF-α chimeric mAb

Indications Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis

Mechanism Neutralises soluble and membrane-bound TNF-α; Fc portion mediates CDC and ADCC against TNF-expressing cells

PBS status ✔ PBS Authority Required

Immunoglobulin Classes

The five immunoglobulin classes (isotypes) differ in structure, distribution, half-life, and effector function. Class-switch recombination (CSR), directed by cytokines from Tfh cells, allows a B cell to change its heavy chain constant region — and therefore its isotype — without altering antigen specificity.

Isotype	Structure	% Serum Ig	Half-life	Key Functions	Clinical Notes
IgG	Monomer (150 kDa); 4 subclasses (IgG1–4)	75–80 %	21–28 days (IgG1/2/3); 21–28 days (IgG4)	Opsonisation, complement activation (IgG1 > IgG3), ADCC, neonatal passive immunity (placental transfer via FcRn)	IgG1: most abundant subclass; IgG2: important for anti-polysaccharide responses (deficiency → encapsulated infections); IgG3: potent complement activator; IgG4: blocking antibody, poor complement activator
IgA	Monomer (serum); dimer with J chain + secretory component (mucosal)	10–15 %	5–6 days (serum); varies (secretory)	Mucosal defence; immune exclusion; neutralisation; anti-inflammatory at mucosal surfaces	IgA deficiency (sIgAD): most common primary immunodeficiency (~1 in 500); anti-IgA antibodies in IgA-deficient patients may cause anaphylaxis with blood products containing IgA
IgM	Pentamer (900 kDa) with J chain	5–10 %	5 days	First-line antibody in primary response; potent classical complement activation; natural antibodies	Pentameric structure provides 10 antigen-binding sites → exceptionally high avidity; cannot cross placenta; elevated in early infection, class-switched memory → IgG
IgE	Monomer (190 kDa)	< 0.01 %	2 days (serum); weeks when bound to FcεRI on mast cells	Type I hypersensitivity (allergic); defence against helminths; mast cell and basophil activation via FcεRI	Lowest serum concentration but highest-affinity Fc receptor (Kd ~10⁻¹⁰ M); basis of allergy and anaphylaxis; targeted by omalizumab
IgD	Monomer (185 kDa)	< 1 %	2.8 days	Co-expressed with IgM on naïve B cells as BCR; role in B cell maturation and innate antimicrobial peptide induction	Function poorly understood; elevated in some chronic infections; IgD myeloma is rare (~1–2 % of myeloma cases)

IgG Subclasses — Clinical Significance

IgG subclass deficiencies are a recognised cause of recurrent infections in Australian patients, particularly IgG2 deficiency, which impairs responses to polysaccharide antigens. The Australasian Society of Clinical Immunology and Allergy (ASCIA) recommends IgG subclass measurement when total IgG is normal but clinical suspicion of humoral deficiency remains high.

🧪

IgG Subclass Reference Ranges (Adult)

Varies by laboratory — Australian reference intervals

IgG1 3.8–9.3 g/L (60–70 % of total IgG)

IgG2 2.4–7.0 g/L (20–30 % of total IgG)

IgG3 0.2–1.1 g/L (5–8 % of total IgG)

IgG4 0.1–1.0 g/L (1–4 % of total IgG)

Immunoglobulin Replacement Therapy in Australia

When humoral immunity is severely impaired, replacement with pooled human immunoglobulin is the cornerstone of management. Australian immunoglobulin products are supplied by the National Blood Authority (NBA) under the national blood arrangements.

💊

Intravenous Immunoglobulin (IVIg)

Intragam P® 6 % / 12 % (CSL Behring) · Privigen® (CSL Behring)

Replacement dose 400–600 mg/kg every 3–4 weeks

Immunomodulatory dose 1–2 g/kg (divided over 2–5 days)

Route IV infusion (hospital-based)

Adverse effects Headache, flushing, anaphylaxis (IgA-deficient patients), aseptic meningitis, haemolysis, thromboembolism

PBS status ✔ PBS Authority Required — managed under NBA national arrangements

💊

Subcutaneous Immunoglobulin (SCIg)

Hizentra® 20 % (CSL Behring) · Cuvitru® (Takeda)

Dose 100–200 mg/kg per week (or equivalent loading then maintenance)

Route SC infusion (home-based, self-administered after training)

Advantages Reduced systemic adverse effects, no IV access required, patient autonomy, stable serum IgG levels

PBS status ✔ PBS Authority Required — managed under NBA national arrangements

Complement Activation

The complement system comprises over 30 soluble and membrane-bound proteins that form an enzymatic cascade, bridging innate and adaptive immunity. Complement is activated through three convergent pathways that share a common terminal pathway leading to formation of the membrane attack complex (MAC).

Three Activation Pathways

Classical Pathway

Antibody-Dependent

Initiated by C1q binding to antigen–antibody complexes (IgG or IgM). C1q undergoes conformational change activating serine proteases C1r and C1s, which cleave C4 and C2 to form C3 convertase (C4b2a).

Link to humoral immunity: direct bridge between antibody and complement

Lectin Pathway

Pattern Recognition

Mannose-binding lectin (MBL) or ficolins recognise conserved carbohydrate patterns (mannose, N-acetylglucosamine) on microbial surfaces. MBL-associated serine proteases (MASP-1, MASP-2) cleave C4 and C2 → C3 convertase (C4b2a), same as classical pathway.

Antibody-independent; important early defence before adaptive immunity develops

Alternative Pathway

Spontaneous C3 Hydrolysis

Continuous low-level hydrolysis of C3 ("tick-over") generates C3(H₂O), which binds Factor B. Factor D cleaves Factor B → C3 convertase (C3bBb), stabilised by properdin. Amplification loop: deposited C3b participates in more C3 convertase formation → exponential amplification.

Always active; provides constant immune surveillance

Terminal Pathway & Membrane Attack Complex

All three pathways converge at C3 cleavage. C3 convertases cleave C3 into C3a (anaphylatoxin) and C3b (opsonin). Addition of C3b to C3 convertases generates C5 convertases (C4b2a3b or C3bBb3b), which cleave C5 into C5a (potent anaphylatoxin and chemotactic factor) and C5b. C5b sequentially recruits C6, C7, C8, and multiple C9 molecules to form the C5b–9 membrane attack complex (MAC), which creates a transmembrane pore causing osmotic lysis of the target cell.

Biological Effects of Complement

Product	Function	Mechanism
C3a, C5a	Anaphylatoxins	Mast cell degranulation → histamine release → vasodilation, increased vascular permeability. C5a is the most potent chemoattractant for neutrophils.
C3b, iC3b, C3d	Opsonins	Covalently bind pathogen surfaces. Phagocytes recognise C3b via CR1 (CD35) and iC3b via CR3 (CD11b/CD18) and CR4 (CD11c/CD18), enhancing phagocytosis.
C3d	B cell co-stimulation	C3d bound to antigen engages CR2 (CD21) on B cells, lowering the activation threshold by up to 1,000-fold — linking complement to humoral immunity.
C5b–9 (MAC)	Direct cytolysis	Forms 10 nm pore in target cell membrane → osmotic lysis. Particularly effective against Gram-negative bacteria (thin peptidoglycan wall).
C3b-bound immune complexes	Immune complex clearance	Erythrocyte CR1 binds C3b-opsonised immune complexes → transported to liver and spleen → stripped by fixed macrophages. Deficiency → SLE-like immune complex disease.

Complement Deficiencies & Clinical Syndromes

Deficiency	Association	Clinical Presentation
C1q, C2, C4 (early classical)	Systemic lupus erythematosus (SLE)	Immune complex clearance failure → SLE-like disease (C1q deficiency: ~93 % develop SLE); also recurrent encapsulated bacterial infections
C3	Severe recurrent infections	Opsonisation and MAC formation impaired → life-threatening infections with S. pneumoniae, N. meningitidis, H. influenzae; membranoproliferative glomerulonephritis
C5–C9 (terminal)	Neisseria infections	MAC formation absent → recurrent invasive meningococcal disease (bacteraemia, meningitis); other infections less affected as opsonisation intact
MBL	Increased infection susceptibility (variable)	Common polymorphism (~5 % homozygous deficient); clinically significant mainly in infancy or immunocompromised
C1-inhibitor	Hereditary angioedema (HAE)	Uncontrolled contact/kallikrein pathway → bradykinin excess → recurrent episodes of non-pitting subcutaneous/submucosal oedema (face, larynx, GI tract, extremities)
Factor H, Factor I	Atypical haemolytic uraemic syndrome (aHUS)	Uncontrolled alternative pathway activation → complement-mediated endothelial injury → thrombotic microangiopathy

⚠️

Investigation of complement deficiency: The CH50 (total haemolytic complement) assay assesses the classical pathway; a CH50 of zero indicates complete absence of one or more classical pathway components. The AP50 assay assesses the alternative pathway. Individual C3 and C4 levels by nephelometry are widely available in Australian laboratories (MBS item 69440). If complement deficiency is suspected, refer to a clinical immunologist for specialised testing and genetic confirmation.

Complement-Targeted Therapies — Available in Australia

💊

Eculizumab

Soliris® · Anti-C5 humanised mAb

Indications PNH, aHUS, generalised myasthenia gravis, neuromyelitis optica

Mechanism Binds C5, preventing cleavage to C5a and C5b → blocks MAC formation and C5a-mediated inflammation

Adult dose 900 mg IV weekly × 4, then 1200 mg IV every 2 weeks

Key risk Meningococcal infection — meningococcal vaccination mandatory before initiation

PBS status ✔ PBS Authority Required — Life-saving drugs programme

💊

Ravulizumab

Ultomiris® · Long-acting anti-C5 mAb

Indications PNH, aHUS

Dose Weight-based loading, then maintenance IV every 8 weeks

PBS status ✔ PBS Authority Required

💊

Lanadelumab

Takhzyro® · Anti-kallikrein mAb

Indication Prophylaxis of hereditary angioedema (Type I/II)

Dose 300 mg SC every 2 weeks

Mechanism Inhibits plasma kallikrein → reduces bradykinin generation

PBS status ✔ PBS Authority Required

Investigations

Laboratory assessment of humoral immunity follows a tiered approach, beginning with widely available screening tests and progressing to specialised assays referred to clinical immunology laboratories.

Essential

Quantitative Immunoglobulins (IgG, IgA, IgM)

MBS item 69440 — Nephelometric assay. First-line screening test for suspected humoral deficiency. Age- and sex-adjusted reference ranges essential (paediatric ranges differ significantly). Total IgE measured if allergic disease suspected.

Essential

Specific Antibody Titres (Post-Vaccination)

Measure IgG titres to tetanus, S. pneumoniae serotypes, H. influenzae type b, and hepatitis B surface antigen ≥ 4 weeks after vaccination. Adequate response defined as ≥ 4-fold rise or protective titre (anti-pneumococcal ≥ 1.3 µg/mL for ≥ 70 % serotypes).

Available

IgG Subclasses (IgG1–4)

MBS item 69440. Indicated when total IgG is normal but clinical suspicion persists. IgG2 deficiency associated with impaired anti-polysaccharide antibody responses.

Available

Complement Assays

CH50 (classical pathway), AP50 (alternative pathway), C3, C4 — available at major laboratories. Functional haemolytic assays (CH50/AP50) preferred over individual component levels for screening. C3 and C4 by nephelometry — widely available (MBS item 69440).

Specialist

B Cell Subset Analysis (Flow Cytometry)

CD19⁺/CD20⁺ total B cells; naïve (CD27⁻IgD⁺), memory (CD27⁺IgD⁻), switched memory (CD27⁺IgD⁻), and transitional (CD24hiCD38hi) subsets. Essential for classification of CVID (Freiburg and Euroclass classifications). Referred to specialised immunology laboratories.

Specialist

Lymphocyte Proliferation Assays

B cell proliferation to pokeweed mitogen (PWM) or anti-IgM ± CD40L. Assesses functional B cell activation capacity. Not routinely available — referral to tertiary immunology centre.

Referral

Genetic / Genomic Testing

Targeted gene sequencing for suspected monogenic disorders (BTK for XLA, CD40L for X-linked hyper-IgM, AID/UNG for autosomal hyper-IgM). Next-generation sequencing panels for primary immunodeficiency available via specialised centres (e.g., Royal Children's Hospital Melbourne, Westmead Children's Hospital Sydney). MBS genomic testing item 73390 may apply.

ℹ️

When to refer to clinical immunology: Refer for specialist evaluation if total IgG is < 2 SD below age-matched mean, if there is a clinical pattern of recurrent sinopulmonary/encapsulated bacterial infections with inadequate vaccine responses, or if complement deficiency (CH50 = 0) is identified. Australian clinical immunologists are listed on the ASCIA website (www.allergy.org.au).

Special Populations

🤰 Pregnancy

IgG Placental Transfer

IgG is actively transported across the placenta via the neonatal Fc receptor (FcRn) from ~13 weeks' gestation, with peak transfer in the third trimester. Premature infants (< 32 weeks) have significantly lower IgG levels, increasing susceptibility to infection.

CVID in Pregnancy

Continue IVIg/SCIg replacement throughout pregnancy — target trough IgG ≥ 7 g/L. Immune thrombocytopenic purpura (ITP) and autoimmune haemolytic anaemia may flare during pregnancy in CVID patients. Monitor closely.

Hereditary Angioedema

Attacks may worsen during pregnancy. C1-inhibitor concentrate (Berinert®) is first-line acute and prophylactic therapy — considered safe in pregnancy. Lanadelumab data in pregnancy limited; discuss risks with clinical immunologist.

👶 Paediatrics

Neonatal Immunoglobulin

Newborns rely on passively transferred maternal IgG (predominantly IgG1). Serum IgG declines to nadir at 3–6 months before the infant's own production increases. Normal adult IgG levels are not reached until age 5–6 years.

Transient Hypogammaglobulinaemia of Infancy (THI)

IgG < 2 SD for age with normal B cell numbers, typically resolving by age 2–4 years. Most common cause of hypogammaglobulinaemia in infants. Observation with immunoglobulin monitoring is appropriate if infections are mild; immunoglobulin replacement if severe.

XLA Diagnosis

Suspect in males < 6 months with absent B cells (CD19⁺ < 1 %) and very low IgG/IgA/IgM. BTK gene mutation analysis confirms. Commence immunoglobulin replacement promptly — SCIg preferred in paediatric patients for home-based therapy and reduced systemic adverse effects.

👴 Elderly

Immunosenescence

Ageing is associated with declining naïve B cell output, accumulation of age-associated B cells (ABCs), reduced somatic hypermutation efficiency, and impaired vaccine responses. Total IgG may remain normal while functional antibody quality (affinity, breadth) deteriorates.

Secondary Hypogammaglobulinaemia

CLL and myeloma (diagnoses increasing with age) frequently cause hypogammaglobulinaemia. Chronic corticosteroid use, immunosuppressive therapy, and protein-losing conditions (nephrotic syndrome, protein-losing enteropathy) also contribute.

🫘 Renal Impairment

Nephrotic Syndrome & IgG Loss

Urinary IgG loss in nephrotic syndrome contributes to hypogammaglobulinaemia and increased infection risk, particularly with encapsulated organisms. Monitor serum IgG in patients with persistent nephrotic-range proteinuria.

Complement in Kidney Disease

Complement dysregulation underlies C3 glomerulopathy, aHUS, and post-infectious glomerulonephritis. Anti-Factor H antibodies and genetic testing for complement regulatory proteins guide therapy (eculizumab for aHUS).

🦠 Immunocompromised

Rituximab-Induced Hypogammaglobulinaemia

Prolonged rituximab use (≥ 4 cycles) may cause persistent hypogammaglobulinaemia due to impaired B cell reconstitution. Monitor IgG levels before each cycle and for 12 months post-treatment. Consider immunoglobulin replacement if IgG < 4 g/L with recurrent infections.

Post-Transplant

Haematopoietic stem cell transplant (HSCT) patients lose humoral immunity during immune reconstitution; immunoglobulin replacement indicated until IgG > 5 g/L and vaccine responses recover (typically 6–12 months post-transplant).

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Infection Burden

Aboriginal and Torres Strait Islander peoples experience significantly higher rates of invasive pneumococcal disease, Haemophilus influenzae type b (Hib) infection, and meningococcal disease compared with non-Indigenous Australians. Chronic suppurative otitis media (CSOM) affects up to 50 % of Indigenous children in remote communities, reflecting both environmental factors and potential differences in mucosal humoral immune responses (sIgA function).

Vaccination Coverage

The National Immunisation Programme provides funded pneumococcal conjugate vaccine (13vPCV) for all Aboriginal and Torres Strait Islander children, with an additional 23vPPV booster at age 4 years in high-risk jurisdictions (NT, QLD, SA, WA). Despite this, vaccination timeliness remains lower in some remote communities. Outreach immunisation programmes and opportunistic vaccination in community health centres are essential strategies endorsed by RACGP and NACCHO.

Diagnostic Access

Access to clinical immunology specialists and laboratory testing for humoral immune deficiency is severely limited in remote and very remote Australia. Serum immunoglobulin quantification and complement assays require transport of samples to metropolitan laboratories. Telehealth consultations with clinical immunologists, now MBS-rebatable under item 91822, have improved access but logistical barriers remain significant.

Immunoglobulin Replacement

SCIg home therapy is particularly advantageous for Aboriginal and Torres Strait Islander patients in remote settings, as it eliminates the need for repeated travel to regional hospitals for IVIg infusions. Training programmes for community health workers in SCIg administration have been piloted successfully in the Northern Territory and Far North Queensland.

Rheumatic Heart Disease & Complement

Rheumatic heart disease (RHD) disproportionately affects Aboriginal and Torres Strait Islander peoples, particularly in northern Australia. While the pathogenesis of RHD is primarily T cell–mediated cross-reactivity, complement activation via the classical and lectin pathways amplifies tissue damage. Monitoring complement consumption (low C3/C4) may assist in assessing acute rheumatic fever activity, though this is not yet standard practice and requires further study.

Cultural Safety

Immunological investigations and immunoglobulin replacement therapy must be delivered within a culturally safe framework. This includes acknowledgement of Country, involvement of Aboriginal Health Workers and Practitioners (AHWPs) in care delivery, use of plain-language resources in local languages where appropriate, and respect for family and community decision-making processes. Refer to AIHW and NACCHO frameworks for culturally safe chronic disease management.

📚 References

1. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10th ed. Philadelphia: Elsevier; 2022.
2. Murphy K, Weaver C. Janeway's Immunobiology. 10th ed. New York: Garland Science; 2022.
3. Australasian Society of Clinical Immunology and Allergy (ASCIA). Primary immunodeficiency (PID) guide for health professionals. Sydney: ASCIA; 2024. Available from: https://www.allergy.org.au/
4. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: https://immunisationhandbook.health.gov.au/
5. National Blood Authority (NBA). National Policy on Immunoglobulin Use in Australia. Canberra: NBA; 2023.
6. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186–1205.
7. Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–1507.
8. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–797.
9. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I — molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
10. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework 2023. Canberra: AIHW; 2023.
11. Lucas M, Hugh-Jones K, Welby A, Misbah S, Snowden N, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiency — a practical guide. Clin Exp Immunol. 2010;161(1):1–7.
12. Bousfiha A, Moundir A, Tangye SG, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508–1520.
13. Maurice PD, Maycock EJ, Whyte IM, Bhagwandeen SB. Complement deficiency and disease in Australian patients. Intern Med J. 2003;33(7):316–320.
14. RACGP. Royal Australian College of General Practitioners Red Book: Guidelines for Preventive Activities in General Practice. 10th ed. East Melbourne: RACGP; 2024.